Testing ALK201 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your tumor is measurable on a scan.
- Your cancer has spread or cannot be removed by surgery.
- You are in generally good health (able to do daily activities without help).
- You agree to use birth control for 6 months after the last dose.
- You have not had a live vaccine in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This study tests an investigational drug called ALK-N001 for people with advanced solid tumors that have not responded to standard treatment or cannot tolerate it. It aims to see if the drug can help shrink tumors and improve outcomes.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.